Evidence map›Paper›PMID 25440814›Full record

Observational studyUrology2015

Reclassification rates are higher among African American men than Caucasians on active surveillance.

Debasish Sundi, Farzana A Faisal, Bruce J Trock, Patricia K Landis, Zhaoyong Feng, Ashley E Ross, H Ballentine Carter, Edward M Schaeffer

Open access · greenAbstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Sociodemographic disparities in prostate cancer imaging.Abdominal radiology (New York) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Debasish SundiJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Farzana A FaisalJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Bruce J TrockJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Patricia K LandisJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Zhaoyong FengJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Ashley E RossJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
H Ballentine CarterJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD.
Edward M SchaefferJames Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: eschaeffer@jhmi.edu.
Johns Hopkins University · US

Funding

Urology Research Training GrantT32DK007552 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI COFFEY, DONALD STRALEY · 1987 to 2012
$2.9M
Roles for Phospholipase A2 Signaling in Prostate DevelopmentK08DK081019 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SCHAEFFER, EDWARD MATTHEW · 2008 to 2012
$840k
NIDDK NIH HHS K08 DK081019NIDDK NIH HHS T32 DK007552NIDDK NIH HHS T32DK007552
6 · The paper itself

Abstract

objectiveTo evaluate the risk of reclassification on serial biopsy for Caucasian and African American (AA) men with very low-risk (VLR) prostate cancer enrolled in a large prospective active surveillance (AS) registry.

methodsThe Johns Hopkins AS registry is a prospective observational study that has enrolled 982 men since 1994. Including only men who met all National Comprehensive Cancer Network VLR criteria (clinical stage ≤T1, Gleason score ≤6, prostate-specific antigen [PSA] level <10 ng/mL, PSA density <0.15 ng/mL/cm(3), positive cores <3, percent cancer per core ≤50), we analyzed a cohort of 654 men (615 Caucasians and 39 AAs). The association of race with reclassification on serial biopsy was assessed with competing-risks regressions.

resultsAA men on AS were more likely than Caucasians to experience upgrading on serial biopsy (36% vs 16%; adjusted P <.001). Adjusting for PSA level, prostate size, volume of cancer on biopsy, treatment year, and body mass index, AA race was an independent predictor of biopsy reclassification (subdistribution hazard ratio, 1.8; P = .003). Examining specific modes of reclassification, AA race was independently associated with reclassification by grade (subdistribution hazard ratio, 3.0; P = .002) but not by volume.

conclusionAA men with VLR prostate cancer followed on AS are at significantly higher risk of grade reclassification compared with Caucasians. Therefore, if the goal of AS is to selectively monitor men with low-grade disease, AA men may require alternate selection criteria.

Indexed as

Black or African AmericanWatchful WaitingWhite PeopleAgedBiopsyHumansMaleMiddle AgedProspective StudiesProstatic Neoplasms

Identifiers

PMID25440814
PMCPMC4275346
OpenAlexW2071444587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.